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1 Summary 
Alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) are the 
most frequent conditions leading to elevated liver enzymes and liver cirrhosis, 
respectively, in the Western world. However, despite strong epidemiological 
evidence for combined effects of alcohol consumption and hepatic lipid 
accumulation on the progression of liver injury, the mutual interaction of the 
pathophysiological mechanisms is incompletely understood.  
The aim of this study was to establish an in vitro model for joint effects of alcohol 
and lipids on hepatic steatosis and inflammation. Herein, we particularly wanted to 
assess the role of CYP2E1, which activates several hepatotoxins and contributes 
to alcoholic liver damage and the role of autophagy, which has been emerged as 
new mechanism for alcohol-induced liver injury. Initially, we established the dose 
range in which neither alcohol nor incubation with the free fatty acid (FFA) oleate 
affected viability or mitochondrial activity in primary human hepatocytes (PHH) and 
HepG2 hepatoma cells. Subsequently, we assessed the combined effect of 
alcohol (50 mM) and oleate (0.2 mM) on hepatocellular lipid accumulation and 
inflammation in PHH. Under these conditions, alcohol significantly enhanced 
oleate induced cellular triglyceride content, while alcohol alone had only a minimal 
effect on hepatocellular lipid content. Analysis of heme oxygenase-1 (HMOX-1) 
expression and malondialdehyde levels (MDA) revealed that the combination of 
alcohol and oleate caused significantly higher oxidative stress and lipid 
peroxidation than either of the two substances alone. The CYP2E1 inhibitor 
chlormethiazole and the antioxidant N-acetylcysteine blunted these combined 
effects of alcohol and oleate on hepatocellular lipid accumulation and inflammation 
in PHH. In contrast to HepG2 C34 cells which do not express CYP2E1, HepG2 
E47 cells which express CYP2E1 exhibited similar joint effects of alcohol and 
oleate as observed in PHH. The combination of alcohol and FFA induced also 
significantly autophagy markers more than the each stimulus alone. Inhibition or 
induction of autophagy led to exacerbate or abrogate the combined effects of 
alcohol and FFA on lipid accumulation, lipid peroxidation and inflammation, 
respectively. 
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In summary, our new model allows the investigation of isolated or joint effects of 
alcohol and FFA on hepatocellular lipid metabolisms and inflammatory signaling. 
Our present findings indicate that CYP2E1, CYP2E1-derived reactive oxygen 
species (ROS) and autophagy play a crucial role in mediating the synergistic 
effects of alcohol and lipids on hepatic steatosis, oxidative stress and inflammation
  3 
2 Introduction 
2.1 Liver diseases 
2.1.1 Definition and natural course of liver disease 
Liver diseases can be divided into acute and chronic liver diseases depending on 
the type of pathogens and the scope of injury. For example alcohol or drug 
intoxications and acute viral infections may lead to acute liver injury and death. 
While chronic liver disease could be caused by chronic alcohol consumption or 
drug abuse, genetic alterations, viral infections and by metabolic disorders or by 
any combinations thereof. Fortunately, complete liver failure caused by acute 
injury is a rare condition. However, the main health problem and burden worldwide 
are chronic liver diseases. Here, regardless of the etiology, persistence of hepatic 
injury leads to chronic hepatic inflammation which can lead to liver fibrosis and 
ultimately liver cirrhosis and cancer. 
2.1.2  Non-alcoholic fatty liver disease (NAFLD) 
2.1.2.1 Definition 
Non-alcoholic fatty liver disease (NAFLD) was first described by Ludwig et al. 
(Ludwig et al., 1980) in series of patients with liver disease and it represents a 
range of histological lesions in the liver that occur in individuals who do not 
consume alcohol in quantities that generally are considered to be harmful (alcohol 
intake < 20-30 g/day), These histological changes range from macrovesicular 
steatosis, which is the key histological feature of NAFLD and is considered 
relatively benign, through lobular inflammation (nonalcoholic steatohepatitis 
[NASH]) to variable degrees of fibrosis, cirrhosis and even hepatocellular 
carcinoma (HCC) (Caldwell and Argo, 2010) (Figure  2.1). The most common 
phenotypic manifestations of primary NAFLD/NASH are overweight/obesity, 
visceral adiposity, type 2 diabetes, hypertriglyceridemia and hypertension. 
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Figure 2.1 The spectrum of NAFLD: fatty liver (steatosis hepatis), non-alcoholic steatohepatitis 
(NASH) with or without fibrosis, and liver cirrhosis, which promotes development of liver cancers. 
 
2.1.2.2 Epidemiology of NAFLD/NASH 
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as an 
important public health problem. It is considered the most common cause of 
chronic liver disease in Western countries and USA (Clark et al., 2002; Powell et 
al., 2005). It is a common condition that in significant number of individuals can 
lead to NASH, fibrosis, cirrhosis and liver cancer. NASH, a serious form of 
NAFLD—is predicted to become the leading cause of liver transplantation in the 
USA by the year 2020 (Wree et al., 2013). Because it is often asymptomatic, much 
of the population with this condition may be unaware that they are afflicted.  
Estimates of the prevalence of NAFLD in unselected populations from developed 
countries vary between 20 and 30% (Browning et al., 2004; Jimba et al., 2005; 
Williamson et al., 2011) and even up to 42.6% in diabetic patients (Williamson et 
al., 2011) and approximately 2-3% of the same population will have NASH 
(Neuschwander-Tetri and Caldwell, 2003). NAFLD is closely linked to obesity and 
insulin resistance in most cases in the Western world (Loomba and Sanyal, 2013). 
Similarly, the vast majority of individuals with NAFLD are either overweight 
(BMI > 25 kg/m²) or obese (BMI > 30 kg/m²) (Bacon et al., 1994) and it is 
estimated to be 60–75% in obese persons (Angulo, 2002; Bellentani et al., 2000) 
and even 85-90% in morbidly obese individuals (BMI > 35 kg/m²) (Andersen et al., 
1984; Angulo, 2002). NAFLD has been also considered as the hepatic 
manifestation of the metabolic syndrome (MS), which includes central obesity, 
insulin resistance, dyslipidemia, and hypertension (Bieghs et al., 2012). 
Furthermore, NAFLD increases the risk of liver cancer (hepatocellular carcinoma 
[HCC]) which is now the leading cause of obesity-related cancer deaths in middle-
aged men in the USA (Michelotti et al., 2013). The overall prevalence of NAFLD in 
children is estimated at 3-10% and in some more recent studies was diagnosed in 
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55% of United State children identified by screening and referral (Schwimmer et 
al., 2013). Moreover, a recent report from the national health and nutrition 
examination survey demonstrated that the prevalence of suspected NAFLD  has 
more than doubled over the past 20 years and currently affects nearly 11% of 
adolescents and one-half of obese males (Welsh et al., 2013). 
2.1.2.3 Etiology and pathogenesis of NAFLD/NASH 
Up to date, major gaps remain in our understanding of the etiology of NAFLD. 
Many cases are related to a “Western lifestyle”, i.e. nutrient abundance coupled 
with a sedentary lifestyle; however, it is likely that genetic predisposition and 
environmental factors plays an important, if not decisive, role in determining which 
individuals have a higher risk for development of NAFLD and for its progression. In 
1998 Day and James proposed the ‘two-hit’ hypothesis for the pathogenesis of 
NASH (Day and James, 1998). The ‘first hit’ involves an imbalance in lipid 
metabolism that leads to hepatic lipid accumulation (hepatic steatosis) which 
primers the liver to develop hepatic inflammation upon either a second pathogen 
afflict the liver or  by exposing the liver to a second metabolic stressor (‘second 
hit’) that promotes oxidative stress, mitochondrial dysfunction and dysregulated 
cytokine production and hence steatohepatitis. The ‘two-hit’ model has 
subsequently been revised in recognition that a combination of ‘second hits’ (both 
environmental and genetic) may lead to the development of steatohepatitis (Day, 
2002). A recent study in NAFLD patients, has shown that hepatic steatosis, nearly 
60% arose from free fatty acids (FFAs), whereas de novo fatty acid synthesis 
accounted for 26%, with a much smaller portion of 15% arising from the diet 
(Donnelly et al., 2005). The causes for progression to fibrosis or even cirrhosis in 
some NASH patients are subject of many studies and are often referred to as the 
‘third hit’ (Hellerbrand, 2010). 
2.1.2.4 Risk factors of NAFLD and NASH 
• Obesity: NAFLD may occur in three-quarters of obese people and close to 
20% may have NASH (Wanless and Lentz, 1990). 
• Central adiposity: central adiposity has been shown to be associated with 
NAFLD in normal weight men but with a high waist-to-height ratio (Hsieh 
and Yoshinaga, 1995). 
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• Hypertriglyceridemia: It has been reported that the prevalence of fatty 
liver and or metabolic syndrome is much higher in persons with 
hypertriglyceridemia compared with those with normal triglycerides 
(Nomura et al., 1988; Pinto et al., 2013) 
• Type 2 diabetes mellitus: NAFLD was positively associated with the 
presence of diabetes independent of the degree of obesity (Braillon et al., 
1985). Moreover, the extent of steatosis correlated with the degree of 
impaired glycemic status, independent of degree of obesity (Silverman et 
al., 1990). It has been also reported that the prevalence of NASH in 
diabetics is much higher compared with non-diabetics (Wanless and Lentz, 
1990; Williamson et al., 2011). 
• Metabolic syndrome (insulin-resistance syndrome): Insulin resistance 
has been regarded as central in the pathogenesis of NAFLD (Marchesini et 
al., 1999) and now NAFLD is considered the hepatic manifestation of the 
metabolic syndrome (Kim and Younossi, 2008). 
2.1.2.5 Prognosis and therapy 
In general, the prognosis for simple steatosis is very good; however, NASH can 
progress to cirrhosis and hepatocellular carcinoma in 10-15% of patients. Once 
cirrhosis is present, it is estimated that 30-40% of these patients will progress to a 
liver-related death over a 10-year period (Bacon et al., 1994; Matteoni et al., 1999; 
Powell et al., 1990). Despite increasing understanding of the mechanisms of 
NAFLD pathogenesis, few effective liver-specific therapies are available. Still, 
weight loss, anti-obesity medication, insulin sensitizer agents and anti-oxidants 
appear to exert favorable effects on NAFLD pathology [reviewed in (Dowman et 
al., 2011)]. 
2.1.3 Alcoholic liver disease (ALD) 
2.1.3.1 Definition  
Similar to NAFLD, alcoholic liver disease (ALD) represents a spectrum of liver 
lesions. The spectrum of ALD includes steatosis with or without fibrosis in virtually 
all individuals with an alcohol consumption of >80 g/day, alcoholic steatohepatitis 
(ASH) with variable severity, fibrosis and liver cirrhosis. Once cirrhosis is 
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established, there is a risk for hepatocellular carcinoma (HCC) in some cases 
(Stickel and Hampe, 2012).  
2.1.3.2 Epidemiology and natural course of ALD 
ALD affects millions of patients worldwide each year and about 4% of all global 
deaths are attributed to alcohol-induced liver injuries (Rehm et al., 2009). ALD is 
still one of the most frequent causes for chronic liver disease, not only in Western 
Countries (Barve et al., 2008; Bergheim et al., 2005) but also in Asia (Farrell et al., 
2013) and it is the second most common reason for liver transplantation in the 
United States and Europe (Adachi and Brenner, 2005; Bellentani et al., 1994). 
Multivariate analysis Studies in humans estimate that liver steatosis evolves in 
almost excessive drinkers (consumption of >30 g/day), but only about one-third 
develop significant necroinflammation (alcoholic steatohepatitis [ASH]) and fibrosis 
and only about 10% progress to cirrhosis (Becker et al., 1996; Bellentani et al., 
1997). Among the latter, 1-2% annually develop hepatocellular carcinoma (HCC) 
as a severe complication (Seitz and Stickel, 2007). A dose–response relationship 
for the amount of alcohol consumed and the risk of HCC has been shown (Corrao 
et al., 2004). Moreover, chronic alcohol consumption strikingly increases the risk of 
cirrhosis and HCC in patients with co-existing of hepatitis B and/or hepatitis C 
virus infection or hemochromatosis (Morgan et al., 2004). Noteworthy, women 
have a significantly higher relative risk of developing alcohol-related liver disease 
than men for any given level of alcohol intake. However, a dose-dependent 
increase has been observed in the relative risk of developing alcohol-induced liver 
injury for both men and women, with the steepest increase among women (Becker 
et al., 1996; Bellentani et al., 1997) (Figure 2.2).    
                                            
Figure 2.2 Relationship between the amount of alcohol consumed and the likelihood of developing 
non-cirrhotic or cirrhotic alcoholic liver disease (ALD) (Bellentani et al., 1997). 
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2.1.3.3 Pathogenesis of ALD 
The pathogenesis of ALD is a complex process and that involves several 
mechanisms at different metabolic levels (Scaglioni et al., 2011). The most toxic 
effects of alcohol are closely linked to its toxic metabolites. Therefore, in order to 
understand the underling mechanism of alcohol-induced liver injuries we have to 
know, how alcohol is metabolized in the liver and the consequences of its 
metabolites on the status and function of the liver. Additional to alcohol 
hepatotoxic effects, alcohol consumption can lead to an increased uptake of 
endotoxins from gut bacteria which contribute to necroinflammation response and 
fibrosis progression via various molecular mechanisms including tumour necrosis 
factor (TNF) and the CD14/toll-like receptor-4 complex to produce ROS via 
NADPH oxidase [reviewed in (Altamirano and Bataller, 2011)]. 
2.1.3.3.1 Hepatic alcohol metabolism 
Alcohol (ethanol, C2H5-OH) undergoes enzymatically-catalyzed oxidative 
metabolism to acetaldehyde (CH3-CHO) by alcohol dehydrogenase (ADH), which 
is located in the cytosol of hepatocytes, and by the microsomal ethanol oxidizing 
system (MEOS) cytochrome P450 2E1 (CYP2E1) in the microsomes, and a minor 
alcohol amount by catalase in the peroxisomes (Figure 2.3).  
 
Figure 2.3 Oxidative ethanol metabolism in the liver cells (hepatocytes) (Zakhari, 2006). 
 
The resulted acetaldehyde is further oxidized by acetaldehyde dehydrogenase 
(ALDH) to acetate (CH3COO−) which released to blood circulation or enters citrate 
cycle. These biochemical processes lead to hepatic lipid accumulation, reactive 
oxygen species (ROS) production and oxidative stress which lead in significant 
fraction of patients to hepatic fibrosis, cirrhosis and liver cancer (HCC).  
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2.1.3.3.2 Alcohol-induced hepatocellular lipid accumulation 
Excessive neutral fat accumulation in the liver (hepatic steatosis) is the most 
common and earliest response of the liver to chronic alcohol consumption (Purohit 
et al., 2004). The mechanisms underlying alcohol-induced hepatic steatosis are 
complex, involving the disturbance of several signaling pathways like adenosine 
monophosphate -activated protein kinase (AMPK) pathway (You et al., 2004) and 
some enzymes like sterol regulatory element binding protein 1 (SREBP-1) which is 
activated to induce a higher expression of lipogenic enzymes (You et al., 2002) 
including fatty acid synthase (FASN), acyl CoA carboxylase (ACC), stearoyl CoA 
desaturase (SCD-1) and diacylglycerol acyltransferase (DGAT) (Carrasco et al., 
2001; Wang et al., 2010) or by inhibition of lipid oxidation by inhibition of 
peroxisome proliferator-activated receptor alpha (PPAR alpha) (Galli et al., 2001). 
Moreover, recent studies have shown a crucial role of CYP2E1 in the underlying 
machanisms of alcohol-induced hepatic steatosis (Wu et al., 2010; Wu et al., 
2012).  
2.1.3.3.3 Alcohol-induced ROS production and hepatic oxidative 
stress 
Alcohol metabolism produced acetaldehyde, a highly toxic and mutagenic 
molecule, and increases oxidative stress by the production of ROS and lipid 
peroxides such as 4-hydroxy 2,3-nonenal, 4-hydroxy-2,3- alkenals and 
malondialdehyde (MDA) (Wu and Cederbaum, 2009). Many processes and factors 
are involved in causing alcohol-induced oxidative stress, including: 
• Changes in the NAD+/NADH ratio in the hepatocytes. 
• Production of acetaldehyde during alcohol metabolism, which through its 
interactions with proteins and lipids also can lead to radical formation and 
cell damage. 
• Damage to the mitochondria resulting in decreased adenosine triphosphate 
(ATP) production. 
• Alcohol-induced oxygen deficiency (i.e., hypoxia), especially in the 
pericentral region of the liver where extra oxygen is required to metabolize 
alcohol. 
• Alcohol-induced increase in the ability of the bacterial product endotoxin to 
enter the bloodstream and liver, where it can activate certain immune cells. 
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• Induction of cytochrome P450 2E1 (CYP2E1) activity, which metabolizes 
alcohol and other molecules and generates ROS in the process. 
• Alcohol-induced increases in the levels of free iron, which can promote 
ROS generation. 
• Effects on antioxidant enzymes and chemicals, particularly glutathione 
(GSH). 
• Conversion of the enzyme xanthine dehydrogenase into a form called 
xanthine oxidase, which can generate ROS (Wu and Cederbaum, 2009). 
2.1.4  The epidemiology and clinical history of NAFLD and ALD co-
morbidity 
NAFLD/NASH and ALD/ASH are increasingly relevant public health issues, first of 
all because of their close association with the worldwide epidemics of diabetes 
and obesity (Scaglioni et al., 2011). Recent studies have found that alcohol per se 
is a risk factor for obesity through both of its produced metabolic energy and via 
increasing the food intake (Yeomans, 2010). The risk of alcohol consumption and 
obesity-inducing liver injury together is far greater than the risk of a single factor 
inducing liver injury (Shen et al., 2010; Tsai et al., 2012). Thus, obese alcoholics 
have an accentuated elevation in serum transaminase levels (Alatalo et al., 2008; 
Ruhl and Everhart, 2005), and in subjects with heavy or even moderate alcohol 
consumption, obesity is an independent risk factor for the development of both 
acute and chronic alcohol-induced hepatitis and cirrhosis (Figure 2.4) (Liu et al., 
2010; Naveau et al., 1997; Raynard et al., 2002). However, the effect of even 
moderate alcohol consumption on liver enzymes increases with increasing BMI 
(Alatalo et al., 2008) and the raised BMI and alcohol consumption are both related 
to liver disease, with evidence of a supra-additive interaction between the two 
(Hart et al., 2010). Most recently, an interesting epidemiological study in England 
of more than 100,000 women has shown that alcohol consumption accompanied 
with obesity induced liver injury in super additive manner in comparison with non-
obese patients who consumed similar moderate or heavy alcohol amounts (Keller, 
2013). 
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Figure 2.4  Standardised rates (with 95% CI) for liver cirrhosis per 1000 women over 5 years by 
body mass index (BMI) and alcohol consumption (Liu et al., 2010). 
 
2.1.5 The role of CYP2E1 in NAFLD and ALD 
2.1.5.1 Definition 
The cytochrome P450 super family is a group of hemecontaining proteins with 
multiple functions including the metabolism of xenobiotics such as drugs, toxins, 
carcinogens, and endogenous substrates, such as fatty acids and steroids. The 
cytochrome P450 enzymes catalyze a number of chemical reactions such as 
peroxidation, dealkylation, mono-oxygenation, reduction, epoxidation, and 
dehalogenation (Leung and Nieto, 2013). A major function of the cytochrome P450 
system is to convert non-polar to polar compounds for conjugation by phase II 
enzymes or for direct excretion. Toxic metabolites are generated by cytochrome 
P450- mediated metabolism, which in turn causes significant cellular injury. The 
catalytic activity of the cytochrome P450 enzymes requires oxygen activation, 
which results in the generation of ROS such as superoxide anion (O2.-) hydrogen 
peroxide (H2O2), and hydroxyl radical (.OH) (Leung and Nieto, 2013). CYP2E1 
oxidizes ethanol to acetaldehyde, and the 1-hydroxyethyl radical, activates various 
agents (CCl4, acetaminophen, benzene, halothane, halogenated alkanes, and 
alcohols) to reactive products, generates reactive oxygen radical species and can 
be induced by ethanol. Moreover, the ethanol-induced liver pathology correlated 
with CYP2E1 levels and lipid peroxidation. Furthermore, inhibitors of CYP2E1 
prevented the elevation of lipid peroxidation and ethanol- induced liver pathology 
[reviewed in (Cederbaum, 2012)]. CYP2E1 is important not only for alcoholic liver 
disease but it plays also a crucial role in NAFLD, for example it metabolizes 
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polyunsaturated fatty acids such as linoleic acid and arachidonic acid to generate 
ω-hydroxylated fatty acids which could be further transformed by alcohol and 
aldehyde deydrogenases to dicarboxylic fatty acids that can have at high levels 
harmful effects on hepatocytes  (Aubert et al., 2011) (Figure 2.5). 
                              
Figure 2.5 A significant amount of CYP2E1 is produced and activated by alcohol and fatty acids in 
ALD and NAFLD (Leung and Nieto, 2013). 
 
2.1.5.2 The role of CYP2E1 in the pathogenesis of NAFLD 
Several clinical studies and rodent models have recently reported the induction of 
CYP2E1 protein level and/or activity in context of obesity, NAFLD and NASH 
[reviewed in (Aubert et al., 2011)]. Other studies have also reported higher 
CYP2E1 mRNA expression in NAFLD thus suggesting increased rate of 
transcription and/ or higher stability of CYP2E1 transcripts [reviewed in (Aubert et 
al., 2011)]. Many studies have shown the significance of increased CYP2E1 
expression and electron leakage from the mitochondrial respiratory chain in 
inducing oxidative stress in NAFLD [reviewed in (Leung and Nieto, 2013)]. The 
hepatic CYP2E1 content and its activity in obese patients with steatosis and, 
particularly, with steatohepatitis were significantly higher than controls and 
correlated positively with both the severity of the liver damage (Orellana et al., 
2006). Furthermore, CYP2E1 activity correlated with the degree of steatosis 
(Butura et al., 2009). Moreover, CYP2E1 is induced in rats fed a high fat diet 
compared to rats fed a high-sucrose /low fat diet suggesting that the amount of fat 
consumed is critical for CYP2E1 induction (Osabe et al., 2008). These data 
provide evidence that CYP2E1 has a crucial role in the mechanism of liver injury 
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found in obese NAFLD and NASH patients.  These studies suggest also that the 
amount of fat in the liver is important for the pathogenesis of NASH by increasing 
CYP2E1 and by rendering the liver more susceptible to noxious molecules such as 
ROS  and other metabolic stressors like lipid peroxidation which correlated 
positively with CYP2E1 expression in obese patients (Orellana et al., 2006). 
Insulin resistance and hyperinsulinemia play a key role in hepatic steatosis and 
are common to both ALD and NAFLD. (CYP2E1_/_) knockout mice showed 
protection from a high-fat diet-induced insulin resistance with improved glucose 
homeostasis (Zong et al., 2012). 
2.1.5.3 The role of CYP2E1 in the pathogenesis of ALD 
The involvement of cytochrome P450 in alcohol metabolism was first identified by 
Charles S. Lieber in his studies on the microsomal ethanol-oxidizing system 
(MEOS) (Lieber, 1997). Many recent studies have suggested a crucial role for 
cytochrome P450 2E1 in context of alcoholic liver disease (ALD) which can be 
induced 10-20 fold by chronic alcohol consumption (Wang et al., 2009). Alcohol 
induced CYP2E1 activity in a dose and time-dependent manner (Liu et al., 2005) 
and this induction is associated with hepatic steatosis (Lu et al., 2008), ROS 
production, oxidative stress (French, 2013; Gonzalez, 2005; Liu et al., 2005; Lu 
and Cederbaum, 2008) inflammation and fibrosis (Lieber, 2004) and DNA lesions 
(Wang et al., 2009). Moreover, CYP2E1 potentiates nitroxidative stress, gut 
leakage, and endotoxemia; altered fat metabolism; and inflammation contributing 
to hepatic apoptosis and steatohepatitis (Abdelmegeed et al., 2013). Interestingly, 
CYP2E1-expressing cells showed an increase in GSH, glutathione-S-transferase, 
catalase and heme-oxygenase and the treatment of these cells with antioxidants 
prevented the induction of these enzymes suggesting that CYP2E1-derived ROS 
may be responsible for the transcription and activation of the antioxidant genes 
[reviewed in (Leung and Nieto, 2013)]. CYP2E1 also induces other antioxidant 
factors, like Nrf2, to protect the liver against CYP2E1-induced oxidant stress 
(Gong and Cederbaum, 2006). Furthermore, using a co-culture model of HepG2 
cells, which do (E47 cells) or do not (C34 cells) express CYP2E1 with hepatic 
stellate cells (HSC) has shown an increase in intra- and extracellular 
hydrogenperoxide (H2O2), lipid peroxidation, and collagen type I protein in HSC 
co-cultured with E47 cells compared with stellate cells alone or co-cultured with 
C34 cells (Nieto et al., 2002), thus reveals a profibrogenic role of CYP2E1- derived 
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ROS. Recently, a new strategy for treatment of alcohol-induced liver injury has 
emerged, namely the pharmacological inhibition of CYP2E1 which has detrimental 
effects on the liver through free radical formation and lipid peroxidation (Gebhardt 
et al., 1997; Gouillon et al., 2000; Swaminathan et al., 2013). Moreover, 
Chlormethiazole (a CYP2E1 inhibitor) decreased lipopolysaccharide-induced 
inflammation in rat Kupffer cells (hepatic macrophages) with ethanol treatment (Ye 
et al., 2013) which reveals a crucial role of CYP2E1 in alcohol-induced 
steatohepatitis.      
2.1.6 The role of autophagy in NAFLD and ALD 
2.1.6.1 Definition 
Autophagy (Greek ‘‘self eating”) is a highly conserved intracellular catabolic 
pathway for the degradation of long-lived proteins, cytoplasmic lipid droplets and 
organelles that is essential for survival, differentiation, development, and 
homeostasis.  Autophagy principally has an adaptive role to protect organisms 
against diverse pathologies, including infections, cancer, neurodegeneration, 
aging, and heart disease (Levine and Kroemer, 2008). The autophagic process 
includes a series of steps, including initiation, elongation and expansion of the 
phagophore assembly site (PAS), phagophore, formation of double-membrane 
vesicle termed autophagosome, maturation through fusion with the lysosome to 
form an autolysosome, leading to the degradation of the enclosed substances 
together with the inner autophagosomal membrane (Figure 2.6) (Cui et al., 2013). 
The resulting molecules are then recycled back to the cytoplasm for reuse. A 
recent study has shown also that pharmacological promotion of autophagy 
alleviated hepatic steatosis and injury in models of alcoholic as well as non-
alcoholic fatty liver injuries (Lin et al., 2013). Moreover, a new study has shown 
that gene transfer of a master autophagy regulator results in clearance of toxic 
protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency 
(Pastore et al., 2013). 
2.1.6.2 The role of autophagy in NAFLD 
Many metabolic, endougenous and/or exogenous factors affect hepatic autophagy 
regulation in terms of nutritional status (Figure 2.7). For example glucagon 
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released from the pancreas during fasting promotes autophagy, whereas insulin 
released after feeding suppresses autophagy (Dolganiuc et al., 2012). 
     
Figure 2.6 The core molecular machinery of autophagy in mammalian cells. The autophagic 
process in mammalian cells is controlled by the following groups of Atgs: (1) The ULK1 complex 
controls the induction or initiation of autophagy for the formation of PAS and phagophore; (2) The 
Beclin 1-class III PI3K complex controls the nucleation step of autophagosome formation; (3) The 
two ubiquitin-like conjugation systems (the Atg12–Atg5 system and the LC3 system) mediate the 
elongation stage, leading to formation of a complete autophagosome; and (4) The Atg9 retrieval 
process functionally involves a protein complex of Atg18 and Atg2 (Cui et al., 2013). 
 
In the liver, autophagy promotes lipid droplets degradation in hepatocytes 
(macrolipophagy) (Dong and Czaja, 2011). The lipid droplets become trapped 
inside the double-membrane vesicle (autolipophagosome) and are infused with 
lysosomes, where they are degraded to fatty acids (Figure 2.7). Recently, a novel 
in vitro study has shown that increased autophagy, leads to a greater breakdown 
of stored lipids to supply fatty acids for β-oxidation or for other uses and oppositely 
pharmacological inhibition of autophagy with 3-methyladenine (3-MA) significantly 
increased hepatocyte TG content in the absence or presence of exogenous lipid 
supplementation (Singh et al., 2009). In the same study, hepatocyte-specific Atg7-
knockout mice had markedly increased hepatic steatosis (Singh et al., 2009). 
Interestingly, restoration of Atg7 expression results in significant reduction in 
obesity-induced ER stress in the liver of ob/ob mice, rescues the defects in insulin 
receptor signaling, reduces serum insulin level, improves glucose tolerance and 
whole body insulin sensitivity through the suppression of hepatic glucose 
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production and enhancement of insulin-stimulated glucose disposal in the 
periphery, and decreases hepatic fatty acid infiltration and liver triglyceride content 
[reviewed in (Rautou et al., 2010)]. 
                     
Figure 2.7 Fatty liver disease and metabolic syndrome. Autophagy functions in the basal turnover 
of lipids by engulfing and degrading lipid droplets. Autophagy is inhibited by the insulin-amino acid-
mTOR signaling pathway via both short-term and long-term regulation mechanisms (Rautou et al., 
2010). 
 
2.1.6.3 The role of autophagy in ALD 
Analysis the hepatocytes of chronic alcohol-fed mice revealed fourfold higher 
autophagosomes formation than in cells of control animals. These results were 
confirmed by immunoblot analyses of light chain protein (LC3-II), an essential 
protein in autophagy levels (Ding et al., 2010; Thomes et al., 2012). Of note, this 
induction of autophagy required CYP2E1-mediated alcohol metabolism and ROS 
production (Ding et al., 2010). However, recent studies identified alcohol-induced 
autophagy in primary hepatocytes and in hepatoma cells expressing alcohol 
dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1) as protective 
mechanism against ethanol-induced toxicity and it seemed to be selective for 
damaged mitochondria and accumulated lipid droplets, but not for long-lived 
proteins, which could account for its protective effects (Ding et al., 2010; Ding et 
al., 2011; Wu et al., 2012). Moreover, induction of autophagy has been shown to 
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reduce steatosis and to protect from hepatotoxicity in models of acute or chronic 
ethanol exposure (Ding et al., 2010; Wu et al., 2010; Wu et al., 2012; Yang et al., 
2012). In accordance, inhibition of autophagy using 3-MA exacerbate the toxic 
effects of ethanol in different in vitro and in vivo alcohol models (Ding et al., 2011; 
Wu et al., 2010; Wu et al., 2012). Furthermore, a recent study has shown that 
autophagy promotes fibrogenesis in activated hepatic stellate cells (HCS) in mice 
and in human tissues via digestion the stored lipids in HCS in order to offer the 
required energy source for their activation (Hernandez-Gea et al., 2012). 
 
2.2 Aim of the thesis 
The aim of this thesis was to establish an in vitro model to analyze the combined 
effects of alcohol and free fatty acids (FFA) on hepatocellular lipid accumulation 
and inflammation and to investigate the role of CYP2E1 and autophagy in these 
pathophysiological mechanisms. 
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3 Materials and Methods 
3.1 Chemicals and Reagents 
Agarose SeaKem ® LE Biozym, Hess/Oldendorf, Germany 
Agar Difco Laboratories, Augsburg, Germany 
Ampicillin Sigma-Aldrich, Deisenhofen, Germany 
Bovine Serum Albumin (BSA) Sigma, Steinheim, Germany 
β-Mercaptoethanol Sigma-Aldrich, Deisenhofen, Germany 
Chlormethiazole (CMZ) Sigma-Aldrich, Deisenhofen, Germany 
Collagenase type IV Sigma-Aldrich, Hamburg, Germany 
DMEM medium PAA Laboratories, Cölbe, Germany 
DMSO Sigma-Aldrich, Deisenhofen, Germany 
DNAse Qiagen, Hilden, Germany 
Ethanol  Otto Fischar GmbH & Co. KG, Germany 
FCS (fetal calf serum) PAN-Biotech, Aidenbach, Germany 
Gentamycin Invitrogen, Karlsruhe, Germany 
GIBCO medium (Hepatozyme-SFM) Invitrogen, Carlsbad, USA 
Milk powder Carl Roth, Karlsruhe, Germany 
N-acetyl cystein Sigma-Aldrich, Deisenhofen, Germany 
Oleic acid Sigma, Steinheim, Germany 
p-Nitrophenol Sigma-Aldrich, Germany 
p-Nitrocatechol Sigma-Aldrich, Germany 
PBS buffer PAA, Pasching, Austria 
Penicillin Invitrogen, Karlsruhe, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Germany 
Ponceau-S solution Applichem, Darmstadt, Germany 
Rapamycin Sigma-Aldrich, Deisenhofen, Germany 
Sodium dodecyl sulfate Roth, Karlsruhe, Germany 
Sodium hydroxide Roth, Karlsruhe, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
Triton X-100                                            Sigma-Aldrich, Deisenhofen, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
Trypan blue solution Sigma-Aldrich, Deisenhofen, Germany 
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3-methyladenine 
  
Sigma-Aldrich, Deisenhofen, Germany 
3.2 Laboratory expendables 
CryoTube vials Nunc, Roskilde, Denmark 
Pipet tips 
(10, 20, 100 und 1000 µl) 
Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml) Corning, New York, USA 
Glassware (various) Schott, Mainz, Germany 
Multiwell plates Corning, New York, USA 
Pipettes (stripettes ®) 
(5, 10, 25, 50 ml) 
Corning, New York, USA 
Reaction vessels (1.5 and 2 ml) Eppendorf, Hamburg, Germany 
Strip tubes (0.2 ml) Peqlab, Erlangen , Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
  
3.3 Laboratory instruments 
Heating block: 
Thermomixer comfort Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
LightCycler® Real-Time PCR System Roche Diagnostics, Mannheim, 
Germany 
Pipettes: 
Eppendorf Research  
(1000 µl, 200 µl, 100 µl, 20 µl, 10 µl, 
2 µl) Eppendorf, Hamburg, Germany 
Pipette controllers: 
Accu-jet® Brand, Wertheim, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker IKA® Werke, Staufen, Germany 
Power Supplies: 
Consort E145 
 
Peqlab, Erlangen, Germany 
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Power Supply-EPS 301 Amersham Biosciences, Munich, 
Germany 
Spectrophotometer: 
EMax® Microplate Reader 
SPECTRAFluor Plus 
 
MWG Biotech, Ebersberg, Germany 
Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, 
Germany 
Centrifuges: 
Biofuge fresco 
Megafuge 1.0 R 
 
Heraeus, Hanau, Germany 
Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 with  
ALTRA20 soft imaging system 
 
Olympus Hamburg, Germany 
 
3.4 Buffers 
PBS buffer 140 mM NaCl  
 10   mM KCl  
 6.4  mM Na2HPO4  
 2     mM KH2PO4 pH 7.4 
    
TE buffer 10   mM Tris/HCl  
 1     mM EDTA pH 8.0 
    
HEPES Buffer  
(100 mM) 
70     ml  
2.383 g 
ultrapure water 
HEPES                         
 
pH 7.4 
 
 
 
   
Krebs-Ringer 
HEPES buffer  
  123  mM 
  1.3   mM 
NaCl 
CaCl2 
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   5     mM KCl 
   100  mM HEPES Buffer  
   5      mM D-glucose  
   1.5    % BSA  
   20    mM sodium pyruvate  
   1      mM ascorbic acid     pH 7.4 
3.5 Cell culture 
3.5.1 Cell culture medium 
DMEM (high glucose 
/10%FCS)  
 
4.5 g/l 
 
Glucose 
 300 µg/ml L-Glutamine 
 supplemented with:  
 10% (v/v) FCS 
 400 IU/ml Penicillin 
 50 µg/ml Streptomycin 
  
Primary human hepatocytes 
medium 
HepatoZYME-SFM (Gibco®) (high glucose/ free            
FCS) 
 supplemented with:  
 4 mM L-Glutamine 
 400 IU/ml Penicillin 
 50 µg/ml Streptomycin 
   
Freezing medium 5 Vol 
DMEM (high glucose/10% 
FCS) 
 3 Vol FCS 
 2 Vol DMSO 
3.5.2 Cultivation of cell lines 
Cell culture work was always performed within a laminar flow biosafety cabinet 
(Hera Safe, Heraeus, Osterode, Germany). Cells were cultivated in a Binder series 
CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 atmosphere at 37°C. For 
passaging adherent cells were washed with PBS and detached with trypsin 
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(0.05%)/EDTA (0.02%) (PAA Laboratories, Cölbe, Germany) at 37°C. 
Trypsinization was stopped by adding equivalent volume of DMEM containing 10% 
FCS. Subsequently, cells were centrifuged at 500 g for 5 min and the obtained cell 
pellet was resuspended in fresh culture medium and distributed to new cell culture 
flasks achieving a cell density thinning factor of 5 to 10. Medium was changed 
every second day. Cell growth and morphology were controlled and documented 
with a microscope (Olympus CKX41 with ALTRA20 Soft Imaging System, 
Olympus, Hamburg, Germany). Cell culture waste was autoclaved before disposal 
with a Sanoclav autoclave (Wolf, Geislingen, Germany).  
3.5.3 Human hepatoma cell line 
HepG2 stably transfected with CYP2E1 plasmid (E47)    
HepG2 stably transfected with control mock plasmid (C34)  
 
Cell lines were kindly provided by Prof. A. I. Cederbaum, New York, NY, USA 
(Wu,D.;  Cederbaum,A.I.2008). The both cell lines were maintained in the same 
medium (DMEM) as HepG2 cells with addition of 400 µg/ml Gentamicin sulfate 
salt (Invitrogen, Karlsruhe, Germany). 
3.5.4 Isolation of primary human hepatocytes 
Primary human hepatocytes (PHH) were isolated in cooperation with Prof. Dr. 
med. Wolfgang Thasler (Experimental Surgical Research, Grosshadern Hospital, 
Munich, Germany) and the center of liver cells isolation “hepacult GmbH” 
(Regensburg, Germany) from human liver resections using a modified two-step 
EGTA/collagenase perfusion procedure (Hellerbrand et al. 2007; Hellerbrand et al. 
2008; Pahernik et al. 1996; Ryan et al. 1993; Weiss et al. 2002). Experimental 
procedures were performed according to guidelines of the charitable state 
controlled foundation HTCR (Human Tissue and Cell Research) with the informed 
patient’s consent. 
3.5.5 Determination of cell number and viability 
Cell number and viability was determined by trypan blue exclusion test. The cell 
suspension was diluted 1:2 with trypan blue solution (Sigma, Deisenhofen, 
Germany) and applied on a Neubauer hemocytometer (Marienfeld GmbH, Lauda-
Königshofen, Germany). Cell with impaired cell membrane integrity are stained 
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blue, and therefore, can be clearly distinguished from intact cells which appear 
white under microscopic inspection. The cell number could be calculated after 
counting cells in all four quadrants of the hemocytometer, each containing sixteen 
smaller squares, with the following equation: 
 
Cell number/ml = Z x DF x 104 ÷ 4 
Z: counted cell number 
DF: dilution factor (in the described procedure the factor is 2) 
 
The ratio of viable cells could be determined by setting the number of unstained 
cells in relation to the total cell number (blue and unstained cells). 
3.6 Isolation and analysis of RNA 
3.6.1 RNA isolation and determination of RNA concentration 
RNA isolation was performed with the RNeasy® mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The principle of RNA 
isolation is based on the absorption of RNA to hydrophilic silicon-gel membranes 
in presence of suitable buffer systems. Biological samples were first lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
containing buffer, which immediately inactivates RNases to ensure isolation of 
intact RNA. To homogenize tissue samples a MICCRA D1 homogenizer (ART 
Prozess- & Labortechnik, Müllheim, Germany) was used. 
After lysis, ethanol has been added to provide ideal conditions for the binding of 
RNA to the silica-gel membranes. Contaminants have been washed away with 
suitable buffers before RNA was eluted in water and stored at -80°C. The 
concentration of RNA was measured with the NanoDrop® ND-1000 UV/VIS 
spectrophotometer (Peqlab, Erlangen, Germany). 
3.6.2 Reverse transcription of RNA to cDNA 
Transcription of RNA to complementary DNA (cDNA) was conducted with the 
Reverse Transcription System Kit (Promega, Mannheim, Germany) which uses 
avian myeloblastosis virus reverse transcriptase (AMV-RT). The working solution 
was pipetted with contamination-free aerosol filter pipet tips after the following 
pipetting scheme: 
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 0.5 µg  RNA 
 4 µl   MgCl2 (25 mM) 
 2 µl  10x reverse transcription buffer 
 2 µl  dNTP mix (10 mM) 
 1 µl  random primer 
 0.5 µl  RNasin ribonuclease inhibitor 
 0.6 µl  AMV RT 
 ad 25 µl H2Odest. 
For reverse transcription samples have been incubated in a GeneAmp® PCR 
cycler (Applied Biosystems, Foster City, USA) for 30 min at 42°C. For denaturation 
of the AMV RT the temperature has been raised to 99°C for 5 min. After cooling 
down to 4°C the obtained cDNA was diluted with 75µl H2Odest.,and used 
immediately or stored at -20°C.  
3.6.3 Quantitative real time polymerase chain reaction 
To quantify the expression of specific mRNA, quantitative real time polymerase 
chain reaction (qRT-PCR) has been performed with the LightCycler® 480 System 
(Roche Diagnostics, Mannheim, Germany). The qRT-PCR is principally based on 
a conventional polymerase chain reaction (PCR), but offers the additional 
possibility of quantification, which is accomplished by fluorescence measurements 
at the end and/or during a PCR cycle. As fluorescent reagent SYBR® Green 
(SensiFAST™ SYBR No-ROX Kit, Bioline, Luckenwalde, Germany) has been 
used. SYBR® Green intercalates with double-stranded DNA whereby the 
fluorescence emission rises significantly. Therefore, the fluorescence signal 
increases proportionally with the amount of PCR products. To quantify the 
expression of a specific gene of interest, the results have been normalized to the 
housekeeper 18s rRNA. The results were evaluated with the LightCycler® 480 
software release 1.5.0 SP4 following the manufacturer’s instructions. qRT-PCR 
was performed according following protocol: 
 2.5 µl  H2Odest. 
 
0.25 µl  forward primer (20 µM) 
 0.25 µl  reverse primer (20 µM) 
 5 µl   SYBR® Green 
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Following standard scheme has been used and adapted to particular primer 
melting point temperature: 
 Initial denaturation:     95°C 2 min 
 Two step PCR (45 cycles):  95°C 5 s 
       60°C 18 s 
 Analysis of melting curve:   95°C  5 s 
       65°C 1 min 
       97°C 0 s 
For validation, after qRT-PCR PCR product has been mixed with loading buffer 
(Peqlab, Erlangen, Germany) and loaded on a agarose gel with ethidium bromide 
(50 µg/100 ml gel) to determine the PCR product length. Each experimental 
condition was performed in triplicates and experiments were repeated at least 
three times. 
Table  3.1 Used primers for qRT-PCR, species: mouse or human 
 
name forward primer reverse primer 
18S 5’- AAA CGG CTA CCA CAT CCA AG 5’- CCT CCA ATG GAT CCT CGT TA 
human IL8 5’-TCT GCA GCT CTG TGT GAA GGT GCA GTT 5’-AACCCTCTGCACCCAGTTTTCCT 
human ICAM1 5’- CTGTCACTCGAGATCTTGAGG 5’- CCTGCAGTGCCCATTATGA 
human HMOX1 5’- GAGTGTAAGGACCCATCGGA 5’-  GCCAGCAACAAAGTGCAAG 
human ACOX1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human ATG7 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human ATG12 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human CPT1A1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human DGAT1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human DGAT2 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human FASN QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human 
PIK3C3(VPS34) QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human p47Phox QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
human SCD-1 QIAGEN QuantiTect Primer Assay QIAGEN QuantiTect Primer Assay 
 
Primers were synthesized by SIGMA Genosys (Hamburg, Germany) or purchased 
as QuantiTect Primer Assays from Qiagen (Hilden, Germany). The lyophilized 
primers (SIGMA Genosys primers) were dissolved in H2Odest. or TE buffer 
(QuantiTect Primer Assays), respectively, and stored at -20°C. 
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3.7  Protein analysis 
3.7.1 Preparation of protein extracts 
To extract whole cell protein from cell lines cultivated in 6-well plates the cell 
culture medium was discarded and cells were washed once with PBS, then 
scraped off with a cell scraper (Corning, New York, USA) and taken up into 350 µl 
cell lysis buffer (Cell Signaling Technology, Boston, USA) supplemented with 
1 mM PMSF and a protease inhibitor cocktail (cOmplete Mini Protease Inhibitor 
Cocktail Tablets from Roche Diagnostics, Mannheim, Germany). Subsequently, 
probes were treated with an ultrasonoscope (Sonoplus hp 70, Bandelin 
electronics, Berlin, Germany) 5 x 3 s at an intensity of 70% for cell lysis. 
Subsequently, the solved proteins were separated from the non-soluble cell 
components by centrifugation at 20,000 g (15 min, 4°C). The protein solution was 
transferred into new reaction tubes and stored at -20°C.  
3.7.2 Determination of protein concentration 
To determine the protein concentrations of protein solutions the BCATM Protein 
Assay Kit (Pierce, Rockford, USA) was used. The assay combines the reduction of 
Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation Cu1+ by bicinchoninic acid 
(BCA). The first step is the chelation of copper with protein in an alkaline 
environment to form a blue-colored complex. In this reaction, known as biuret 
reaction, peptides containing three or more amino acid residues form a colored 
chelate complex with cupric ions in an alkaline environment. One cupric ion forms 
a colored coordination complex with four to six nearby peptides bound. In the 
second step of the color development reaction, BCA, a highly sensitive and 
selective colorimetric detection reagent reacts with the cuprous cation Cu1+ that 
was formed in step 1. The purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper complex 
is water-soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations. 200 µl of alkaline BCA/copper(II) solution (50 parts of 
solution A mixed with 1 part of solution B) was added to 2 µl of protein solution 
using a 96-well plate and were incubated for 15 min at 37°C. Thereafter the purple 
color was measured at 562 nm with a spectrophotometer (EMax® Microplate 
Reader, MWG Biotech, Ebersberg, Germany). The optical absorbance values 
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could be translated into specific protein concentrations by parallel quantification of 
a BSA standard. 
3.7.3 SDS polyacrylamid gel electrophoresis (SDS-PAGE) 
Used buffers: 
Laemmli buffer  62.5 mM Tris/HCl; pH 6.8 
    2% (w/v) SDS 
    10% (v/v) Glycerine 
    5% (v/v) β-Mercaptoethanol 
 
Running buffer  25 mM Tris/HCl; pH 8.5 
    200 mM Glycine  
    0.1% (w/v) SDS 
 
12% Resolving gel  6.6 ml  H2Odest.  
    5.0 ml  1.5 M Tris/HCl; pH 8.8 
    0.2 ml  10% (w/v) SDS 
    8    ml  Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.2 ml  Ammonium persulfate 10% (w/v) 
    0.008 ml TEMED 
 
18% Resolving gel  2.6 ml  H2Odest.  
    5    ml  1.5 M Tris/HCl; pH 8.8 
    0.2 ml  10% (w/v) SDS 
    12  ml  Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.2 ml  Ammonium persulfate 10% (w/v) 
    0.008 ml TEMED 
 
5% Stacking gel  2.7 ml  H2Odest. 
    0.5 ml  1.0 M Tris/HCl; pH 6.8 
    0.04 ml 10% (w/v) SDS 
    0.67 ml Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.04 ml Ammonium persulfate 10% (w/v) 
    0.004 ml  TEMED 
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The protein solutions were heated at 95°C for 5 min in Laemmli buffer and applied 
on a SDS polyacrylamid gel for protein fractionation by size at 35 mA/170 V (XCell 
SureLockTM Mini-Cell, Invitrogen, Karlsruhe, Germany). As size marker HiMark™ 
Pre-Stained High Molecular Weight Protein Standard (Invitrogen, Karlsruhe 
Germany) and peqGOLD Protein-Marker V (Peqlab, Erlangen, Germany) were 
used. 
3.7.4 Western Blotting 
Used buffers: 
Standard transfer buffer:   
                                          10% (v/v) Methanol 
    25  mM Tris 
            190 mM Glycine 
 
To detect the proteins after SDS-PAGE by use of specific antibodies proteins were 
transferred electrophoretically to a nitrocellulose membrane (Invitrogen, Karlsruhe, 
Germany) at 220 mA/300 V for 1.5 h (XCell II Blot Module, Invitrogen, Karlsruhe, Germany). 
To block unspecific binding sites, the membrane was bathed in PBS containing 3% BSA or 
5% milk powder for 1 h at RT. Then, the membrane was incubated with a specific primary 
antibody ( 
 
 
 
 
Table  3.2) over night at 4°C. After washing, the membrane was incubated with a secondary 
horseradish peroxidase (HRP) conjugated antibody ( 
 
 
 
 
Table  3.2) for 1 h at RT. Thereafter, the membrane was washed and incubated 
with ImmunStarTM WesternCTM Kit (BioRad, München, Germany) for 3 min. This 
system utilizes chemiluminescence technology which was detected by the 
ChemiDoc XRS (BioRad, München, Germany) imaging system.  
3.7.5 Analysis of cell culture supernatants 
All analysis were performed at the Department of Clinical Chemistry and 
Laboratory Medicine (University of Regensburg, Germany) using the Advia 1800 
analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). 
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Table  3.2 Used primary and secondary antibodies for Western Blot analysis 
 
Primary antibody Dilution 
rabbit phospho c-Jun  (Cell signalling, Beverly, USA) 1:1000 
rabbit phospho IκΒ−α  (Cell signalling, Beverly, USA) 1:1000 
rabbit phospho JNK (Cell signalling, Beverly, USA) 1:1000 
mouse anti-β-actin (Sigma-Aldrich, Deisenhofen, Germany) 1:20,000 
Secondary antibody  
anti-mouse HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:2000 
anti-rabbit HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:2000 
 
For determination of cytotoxic effects of diverse stimulus, cells (5 x 105 cells per 
well) were seeded in 6 well plates (Corning, New York, USA) and grown overnight 
followed by stimulation with diverse stimulus for another 24 h. Thereafter, 
supernatants were collected and centrifuged at 20,000 g for 5 min to remove 
detached cells and debris. The amount of lactate dehydrogenase (LDH) and 
aspartate aminotransferase (AST) in the supernatants were used as marker for 
cell viability. 
3.8 Functional assays 
3.8.1 Mitochondrial activity assay (XTT) 
Cells viability was quantified with the XTT kit (Roche Diagnostics, Mannheim, 
Germany). The assay is based on the ability of metabolic active cells to reduce the 
tetrazolium salt XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[phenylamino)carbonyl]-2H-tetrazolium hydroxide) to orange colored compounds 
of formazan. The dye formed is water soluble and dye intensity can be read with a 
spectrophotometer at a wavelength of 450 nm and a reference absorbance 
wavelength of 650 nm. The intensity of the dye is proportional to the number of 
metabolic active cells.  
To quantify the effects of alcohol and/or FFA treatment on cells viability, cells were 
seeded in 6-well tissue culture plates (250 000 cells per well) and incubated with 
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stimulants for different time intervals. At the chosen time points XTT reagent was 
added and the intensity of the forming dye was measured 30 min later with an 
EMax Microplate Reader (MWG Biotech, Ebersberg, Germany). Values of optical 
density (OD) at individual time points were corrected for background by 
subtracting the OD value of blank wells without cells. Each experimental condition 
was performed in triplicate and experiments were repeated three times. 
3.8.2 CYP2E1 activity (p-nitrophenol hydroxylation) 
4-Nitrophenol (p-NP) hydroxylation activity in terms of 4-nitrocatechol formation 
was determined in intact cells (Dicker et al., 1990; Perez and Cederbaum, 2001) 
with some modification. Briefly, at first, the cells were pre-incubated with FFA or 
BSA (served as control) for 24 h. Subsequently, cells were stimulated with alcohol 
for16 h. The conditioned media were replaced with Krebs-Ringer HEPES buffer 
pH 7.4 contained (100 µM) p-nitrophenol. The cells were incubated at 37 °C for 12 
h. The reaction was terminated by adding perchloric acid to the reaction mixture 
(final concentration 4%). The mixture was then cooled on ice, and the protein was 
removed by centrifugation at 10,000 g for 5 min. transfer 0.5 ml of the supernatant 
to a clean tube containing 40 µL of 10 M NaOH, the absorbance at 492 nm was 
immediately measured. The product of p-NP hydroxylation (p-Nitrocatechol) was 
calculated using a standard curve of p-Nitrocatechol. 
 
3.9 Lipid assays 
3.9.1 Triglycerides (TG) assay  
To quantify the total hepatic lipids content, lipids were extracted from hepatoma 
cell line using the method of Bligh and Dyer with slight modifications (BLIGH and 
DYER, 1959). In brief, cell pellets were weighed into 0.5 ml of a 
chloroform/methanol mix (2:1 v/v) and incubated for 1 h at room temperature on 
an orbital shaker to extract the lipids. After addition of 200 µl H2Odest., vortexing 
and centrifugation for 5 min at 3000 g, the lower lipid phase was collected and 
dried over night at room temperature. The lipid pellet was then re-dissolved in 
60 µl tert-butanol and 40 µl of a Triton X-114/methanol mix (2:1 v/v), and total 
triglycerides content was quantified using the Triglyceride GPO-PAP Quantification 
Kit from Roche diagnostic (Mannheim, Germany) according to the manufacturer’s 
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instructions. The principle of this assay is based on series of coupled enzymatic 
reactions in which triglycerides are hydrolyzed to produce glycerol. Glycerol is then 
oxidized using glycerol oxidase into Dihydroxy acetone phosphate and Hydrogen 
peroxide (H2O2). 
H2O2 is measured quantitatively in a peroxidase catalyzed reaction that produces a 
color. Absorbance is measured at 540 nm using an EMax Microplate Reader 
(MWG Biotech, Ebersberg, Germany). Each experimental condition was 
performed in triplicates. 
3.9.2 Lipid peroxidation (TBARS assay) 
Lipid peroxidation in hepatoma cell lines was assayed by measuring one of the 
end products of this process, the thiobarbituric acid (TBA)-reactive substances 
(TBARS) using  the method of Ohkawa,H with some modifications. Briefly, 1-2 x 
107 cells were homogenized in 1 ml PBS containing antioxidant Butylated 
hydroxytoluene (BHT) to prevent further oxidation of lipid during sample 
processing and the TBA reaction. The whole cells homogenates were used in this 
assay. 5.2 mg/mL TBA reagent (pH 3.5) and sodium dodecyl sulphate (SDS) were 
added to each sample with volumes proportion (2.5:1:1) respectively. The samples 
were heated with a thermomixer (Eppendorf, Hamburg, Germany) at 95°C for 60 
min. The mixture was then cooled to room temperature in an ice bath for 5 
minutes. The samples were centrifuged at 3000 rpm for 15 min. Supernatants 
were used for the spectrophotometric measurement. The absorbance was 
measured at 540 nm. As 99% TBARS is malondialdehyde (MDA), so lipid 
peroxidation levels of the samples were calculated from the standard curve using 
MDA and expressed as nanomoles of MDA per mg of protein. 
3.9.3 Oil Red O staining 
Cells were washed with PBS and fixed with 10 % Formaldehyd for 5 min at room 
temperature, then formaldehyd was removed and cells were washed with 60% 
isopropanol and leaved to become dry. Subsequently, cells were incubated with 
Oil Red O (Sigma) dissolved in Isopropanol for 30-60 min at room temperature. 
Finally cells were washed 3 times with distilled water and then intracellular lipid 
accumulation was examined and quantified by fluorescence microscope.  
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3.10 Reagent preparation for in vitro experiments 
3.10.1 Oleate preparation 
Oleate (C18:1) is monounsaturated omega-9 fatty acid found in circulation. In 
human blood it is bound to albumin, with a physiologic ratio of fatty acid to albumin 
of approximately 2:1. In states of insulin resistance and obesity (as major risk 
factors for NAFLD/NASH), serum fatty acid levels are commonly elevated, yielding 
ratios as high as 7.5:1 (Kleinfeld et al., 1996). In order to simulate hepatic 
steatosis, we established an in vitro model of oleate-induced fatted cells. Oleic 
acid was complexed to BSA in a molar ratio of approx. 6.7:1, thereby mimicking 
hyperlipidemic conditions.  
Preparation of the oleate stock solution was carried out as described by Cousin et 
al. (Cousin et al., 2001). Briefly, a 100 mM oleic acid stock solution was prepared 
in 0.1 M NaOH by heating at 70 °C. A 10% (w/v) aqueous free fatty acid free BSA 
solution was prepared and maintained at 55 °C in a water bath. 10 mM oleic acid 
1% BSA solution was obtained by complexation of the appropriate amount of oleic 
acid stock solution with 10% BSA at 55 °C for another 30 min. The obtained 
solution was then cooled to 25 °C, filter sterilized and stored at −20 °C until use. 
For in vitro experiments the 10 mM oleate/10% BSA stock solution was heated for 
15 min at 55 °C and subsequently cooled down to working temperature (37 °C) 
before use. Samples indicated as controls received an appropriate amount of a 
vehicle control stock solution, which was prepared analogous to the oleate/10% 
BSA stock solution, except for adding oleic acid. 
 
3.11 Statistical analysis 
Values are presented as mean ± SEM or mean ± SD as indicated. All experiments 
were repeated at least three times. Comparison between groups was made using 
the Student’s unpaired t-test. A p-value < 0.05 was considered statistically 
significant. Calculations were performed using the statistical computer package 
GraphPad Prism (GraphPad Software, San Diego, CA, USA).
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4 Results 
 
As described in the introduction few data are known regarding the underling 
mechanisms for the combined effects of alcohol consumption and obesity. The 
aim of this thesis was to address this issue. In particular, the focus was placed on 
five aspects: 
 
4.1 Establishment an in vitro model for the combined effects of alcohol (Alc) and 
free fatty acids (FFA). 
4.2 The combined effect of alcohol and FFA on hepatocellular lipid accumulation. 
4.3 The combined effects of alcohol and FFA on lipid peroxidation and pro-
inflammatory gene expression. 
4.4 Role of CYP2E1 in joint effects of alcohol and FFA on lipid metabolism and 
pro-inflammatory gene expression. 
4.5 Role of autophagy in joint effects of alcohol and FFA on lipid metabolism and 
pro-inflammatory gene expression. 
4.1 Establishment an in vitro model for the combined effects 
of alcohol and FFA 
We initially established a dose range in which neither alcohol (Alc) nor free fatty 
acid oleate (FFA) exhibited cytotoxic effects. Namely, PHH were incubated with 
serial concentrations of alcohol or FFA (oleate) for 48 h. After 48 h microscopic 
images were taken (Figure 4.1).  
 
 
 
 
 
Figure 4.1 PHH, 48 h stimulation with alcohol or FFA. Microscopic images (10X).  
Alc 100 mM Alc 200 mM Alc 400 mM Alc 50 mM Alc 0 mM 
FFA 0.0 mM  FFA 0.1 mM FFA 0.2 mM FFA 0.4 mM 
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Then, supernatants were collected and alanine transaminase (ALT), aspartate 
transaminase (AST) and hepatocellular mitochondrial activity (XTT assay) were 
assayed (Figure 4.2) 
 
 
 
Figure 4.2 48 h after alcohol or FFA stimulation vitality was measured as cell membrane lysis and 
release of transaminases into supernatants (A) ALT leakage (B) AST leakage. (C) XTT activity was 
measured as marker for cells viability 
 
Next we analyzed the effect of each alcohol and FFA on lipid accumulation in 
theses dose ranges and observed a dose-dependent induction of triglyceride (TG) 
levels by alcohol as well as FFA (Figure 4.3). 
To study the combined effect of alcohol and FFA on primary human hepatocytes 
(PHH) we chose oleate at a concentration of 0.2 mM and an alcohol concentration 
of 50 mM. We have previous shown that hepatocellular steatosis induced by this 
oleate concentration leads to pathological alterations similar to those found in 
hepatic tissue of NAFLD-patients (Dorn et al., 2010; Wobser et al., 2009). 
Furthermore, previous studies revealed that in vitro exposure of hepatic cells to 50 
mM alcohol mimics the situation of “moderate” alcohol consumption in humans 
(Deitrich and Harris, 1996; Jones and Holmgren, 2003). 
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Figure 4.3 Triglyceride assay after 48 h treatment with (A) alcohol or (B) FFA. *: p<0.05 compared 
to control (0 mM). 
 
Our in vitro model was stable along the different experiments. Namely, PHH were 
pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for either additional 24 
h for toxicity and lipid assays or for additional 16 h for mRNA and protein analysis. 
In these concentrations, neither FFA or alcohol alone nor the combination of FFA 
and alcohol affected the viability of PHH in vitro within 48h (Figure 4.4). 
               
 
 
Figure 4.4 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 24 h. (A) Microscopic 
images (B) ALT leakage (C) AST leakage (D) Mitochondrial activity (xtt activity). 
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4.2 Combined effects of alcohol and FFA on hepatocellular 
lipid accumulation 
Analysis of cellular TG levels and oil red O staining showed that alcohol as well as 
FFA induced lipid accumulation in PHH (Figure 4.5). Interestingly, alcohol and FFA 
synergistically led to a significantly higher lipid accumulation in PHH than either of 
the two stimuli alone (Figure.4.5). 
 
             
                           
 
 
Figure 4.5 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 24 h. (A) Triglyceride 
content in PHH was normalized to its total protein content (B) computed quantification of oil red O 
staining (C) microscopic images of Oil red O staining (20X). (*: p< 0.05 compared with control, #: 
p< 0.05 compared with FFA or alcohol).  
 
In search for the underlying mechanisms of the synergistic effect of alcohol and 
FFA on hepatocellular lipid accumulation we analyzed the expression of fatty acid 
synthase (FASN) the key enzymes of hepatic de novo lipogenesis. Alcohol alone 
or FFA alone had slight effects while the FFA-alcohol-combination significantly 
enhanced FASN expression in PHHs (Figure 4.6). Similarly, alcohol and FFA 
synergistically up-regulated the gene expression of stearoyl-CoA desaturase-1 
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(SCD-1), which catalyzes a rate-limiting step in the synthesis of unsaturated fatty 
acids, and diglyceride acyltransferase DGAT2 and DGAT1, which catalyze the 
final step in triglycerides formation from diacylglycerol and Acyl-CoA (Figure 4.6).  
Together, these data show a cooperative effect of FFA and alcohol stimulation on 
lipogenesis and cellular lipid accumulation in PHH in vitro. 
(A)                                         (B)                                       (C)                                         (D) 
 
 
Figure 4.6 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. Analysis of 
heptocellular mRNA levels of (A) FASN (B) SCD-1 (C) DGAT2 and (D) DGAT1 by quantitative RT-
PCR. (*: p< 0.05 compared with control, #: p< 0.05 compared with FFA or alcohol). 
 
4.3 Combined effects of alcohol and FFA on lipid peroxidation 
and inflammation 
In addition to lipid storage, enhanced lipogenesis can induce lipid combustion. 
Alcohol and FFA alone had only slight effects on the gene expression of carnitine 
palmitoyltransferase I (CPT1) and acyl-coenzyme A oxidase 1 (ACOX1), the key 
enzymes of the mitochondrial and peroxisomal beta-oxidation systems, 
respectively (Figure 4.7). However, the combination of alcohol and FFA 
significantly enhanced CPT1 and ACOX1 expression (Figure 4.7) indicating an 
increased oxidation rate of FFA and formation of reactive oxygen species (ROS). 
Accordingly, thiobarbituric acid reactive substance (TBARS) assay revealed a 
marked increase of malondialdehyde (MDA) levels in PHH stimulated with alcohol 
and FFA while alcohol or FFA alone had no or only slight effects (Figure 4.8.A). 
Furthermore, the expression of heme oxygenase-1 (HMOX-1) and NADPH 
oxidase component p47phox was only significantly enhanced in PHH stimulated 
with the combination of alcohol and FFA indicating increased cellular oxidative 
stress (Figure 4.8.B and C). 
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                  (A)                                                                             (B)                                                 
 
Figure 4.7 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. Analysis of 
heptocellular mRNA levels of (A) CPT-1 (B) ACOX-1 by quantitative RT-PCR. (*: p< 0.05 
compared with control, #: p< 0.05 compared with FFA or alcohol). 
 
     (A)                                                    (B)                                                  (C) 
 
Figure 4.8 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for either additional 24 h for TBARS 
assay or for additional 16 h for mRNA analysis. (A) TBARS assay (MDA assay) (B) Analysis of 
heptocellular mRNA levels of HMOX-1 (C) p47Phox by quantitative RT-PCR. (*: p< 0.05 compared 
with control, #: p< 0.05 compared with FFA or alcohol). 
 
Oxidative stress is a known inducer of the transcription factor NFκB, which plays a 
critical role in the pathogenesis of both ALD and NAFLD (Videla et al., 2009). 
NFκB is held inactive in the cytoplasm by its inhibitor IκBα, while phosphorylation 
of IκBα leads to its degradation, and subsequently, NFκB activation. In our in vitro 
model we observed enhanced phospo-IκBα levels in alcohol and FFA stimulated 
PHH indicative of activation of the NFκB pathway, and phospo-IκBα levels were 
further enhanced by combined stimulation with both stimuli (Figure 4.9). 
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Interleukin-8 (IL-8) and intercellular adhesion molecule 1 (ICAM-1) are two pro-
inflammatory genes which are regulated by NFκB and which correlate with 
inflammation in ALD and NAFLD (Chavez-Tapia et al., 2012; Ito et al., 2007). 
Notably, expression levels of IL-8 and ICAM corresponded with phospo-IκBα 
levels in PHH stimulated with alcohol, FFA or their combination (Figure 4.9). 
These findings indicate joint FFA and alcohol on oxidative stress and pro-
inflammatory gene expression in PHH in vitro. 
                                  (A) 
 
                      (B)                                                                          (C) 
 
Figure 4.9 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. (A) Western plotting 
of p-IκBα. β-actin served as control for loading adjustment. (B) Analysis of heptocellular mRNA 
levels of IL-8 (C) ICAM-1 by quantitative RT-PCR. (*: p< 0.05 compared with control, #: p< 0.05 
compared with FFA or alcohol). 
 
4.4 Role of CYP2E1 in joint effects of alcohol and FFA on lipid 
metabolism and pro-inflammatory gene expression 
Ethanol metabolism by CYP2E1 leads to the generation of ROS which promote 
ethanol hepatotoxicity (French, 2013). Furthermore, CYP2E1 carries out omega 
hydroxylation of fatty acids, and plays a critical role in the development and 
progression of NASH (Daly, 2013). To study the role of CYP2E1 in joint effects of 
alcohol and FFA we compared hepatoma HepG2 cells expressing CYP2E1 (E47 
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cells) with control HepG2 C34 cells (mock plasmid) which don’t express CYP2E1 
(Wu and Cederbaum, 2008). In E47 cells but not in C34 cells, combined effects of 
alcohol and FFA on hepatocellular TG accumulation and gene expression of key 
enzymes of lipid metabolism were significantly stronger than effects of alcohol or 
FFA alone (Figure 4.10).  
                      (A) 
 
 
 
 
 
 
 
 
 
      (B)                                                                            (C) 
  
Figure 4.10 HepG2 E47 and HepG2 C34 cells were pre-incubated with 0.2 mM oleate or BSA 
(served as controls) for 24 h. Subsequently, cells were co-incubated with 50 mM alcohol for 
additional 24 h for (A) lipid analysis. Or for additional 16 h for mRNA analysis of (B) SCD-1 (C) 
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FASN (D) DGAT2 and (E) DGAT1 by quantitative RT-PCR. (*: p< 0.05 compared with 
corresponding control, #: p< 0.05 compared with corresponding FFA or alcohol). 
 
Furthermore, lipid peroxidation and the markers of oxidative stress and 
inflammation were significantly stronger than effects of alcohol or FFA alone 
(Figure 4.11).               (A) 
 
 
 
 
 
 
                            
 
 
     
 
 
 
Figure 4.11 HepG2 E47 and HepG2 C34 cells were pre-incubated with 0.2 mM oleate or BSA 
(served as controls) for 24 h. Subsequently, cells were co-incubated with 50 mM alcohol for 
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additional 24 h for (A) TBARS assay, or for additional 16 h for mRNA analysis of (B) CPT-1 (C) 
HMOX-1 (D) ICAM-1 and (E) p47Phox by quantitative RT-PCR. (*: p< 0.05 compared with 
corresponding control, #: p< 0.05 compared with corresponding FFA or alcohol). 
 
To verify the central role of CYP2E1 and ROS-formation in our model, E47 cells 
were co-incubated with 100 µM chlormethiazole (CMZ), a CYP2E1 inhibitor, or 0.2 
mM N-acetyl cystein (NAC), a ROS scavenger. Both CMZ and NAC inhibited 
isolated as well as combined effects of alcohol and FFA on markers of oxidative 
stress and inflammation (Figure 4.12). 
(A)                                                        (B)                                                         (C) 
 
Figure 4.12 HepG2 E47 cells which express CYP2E1 were pre-incubated with 0.2 mM oleate or 
BSA (served as control) for 24 h. Subsequently, some cells were co-incubated with 
Chlormethiazole (CMZ), a CYP2E1 inhibitor (100 µM) or N-acetyl cystein (NAC), a ROS scavenger 
(0.2mM) for 1 h before adding 50 mM alcohol to cultured medium for additional 16 h for mRNA 
analysis of (A) p47Phox (B) HMOX-1 and (C) ICAM-1 by quantitative RT-PCR. (*: p< 0.05 
compared with corresponding control, #: p< 0.05 compared with FFA or alcohol in all experiment 
conditions). 
 
 Also alcohol and FFA effects on FASN, SCD-1 and DGAT1/2 expression were 
almost completely blunted by CMZ or NAC (Figure 4.13). 
(A)                                        (B)                                         (C)                                       (D) 
 
Figure 4.13 HepG2 E47 cells which express CYP2E1 were pre-incubated with 0.2 mM oleate or 
BSA (served as control) for 24 h. Subsequently, some cells were co-incubated with 
Chlormethiazole (CMZ), a CYP2E1 inhibitor (100 µM) or N-acetyl cystein (NAC), a ROS scavenger 
(0.2mM) for 1 h before adding 50 mM alcohol to cultured medium for additional 16 h for mRNA 
analysis of (A) FASN (B) SCD-1 (C) DGAT2 and (D) DGAT1 by quantitative RT-PCR. (*: p< 0.05 
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compared with corresponding control, #: p< 0.05 compared with FFA or alcohol in all experiment 
conditions). 
 
 
Furthermore, CMZ and NAC inhibited both isolated alcohol effects and joint effect 
of FFA and alcohol on CPT1 expression, hepatocellular TG and MDA levels 
(Figure 4.14). 
 
     (A)                                                       (B)                                                       (C) 
 
Figure 4.14 HepG2 E47 cells which express CYP2E1 were pre-incubated with 0.2 mM oleate or 
BSA (served as control) for 24 h. Subsequently, some cells were co-incubated with 
Chlormethiazole (CMZ), a CYP2E1 inhibitor (100 µM) or N-acetyl cystein (NAC), a ROS scavenger 
(0.2mM) for 1 h before adding 50 mM alcohol to cultured medium for additional 24 h for (A) TG 
assay or (B) TBARS assay, or for additional 16 h for mRNA analysis of (C) CPT-1 by quantitative 
RT-PCR. (*: p< 0.05 compared with corresponding control, #: p< 0.05 compared with FFA or 
alcohol in all experiment conditions). 
 
In contrast, isolated effects of FFA on cellular lipid levels, beta-oxidation and lipid 
peroxidation markers were not affected by CMZ or NAC (Figure 4.14). In 
accordance with these results CYP2E1 activity in E47 cells was slightly induced by 
alcohol or FFA alone. Interestingly, alcohol plus FFA induced synergistically the 
CYP2E1 activity which reveals a crucial role of CYP2E1 activation in these 
underling pathophysiological mechanisms (Figure 4.15)  
 
Together, these data indicate that CYP2E1 activation and ROS-formation account 
for the joint effects of alcohol and FFA on cellular lipid accumulation, lipid 
peroxidation and proinflammatory gene expression. 
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Figure 4.15 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. CYP2E1 activity 
assay was achieved after 16 h treatment with alcohol and/or FFA as described in chapter 3.8.2.  
(*: p< 0.05 compared with control, #: p< 0.05 compared with FFA or alcohol). 
 
4.5 Role of autophagy in joint effects of alcohol and FFA on 
lipid metabolism and pro-inflammatory gene expression 
Increasing oxidative stress by alcohol can activate the JNK MAP kinase-signaling 
pathway in CYP2E1-dependent manner, which may lead to JNK-dependent 
induction of autophagy (Ding et al., 2007; Ding and Yin, 2008; Komiya et al., 
2010). Also FFAs have been shown to stimulate autophagy in pancreatic beta-
cells via JNK pathway (Komiya et al., 2010). In our experimental model alcohol or 
FFA stimulation exhibited no or only slight effects on phopsho-JNK and phospho-
cJUN protein levels in PHH compared to control cells (Figure 4.16). However, 
combined stimulation with alcohol and FFA caused a significant increase of 
phopsho-JNK and phospho-cJUN levels (Figure 4.16) indicative for an activation 
of this MAPK-pathway.  
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Figure 4.16 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. Western plotting of 
p-JNK and p-c-JUN. β-actin served as control for loading adjustment. 
 
Furthermore, expression of autophagy-related molecules such as ATG7 and 
ATG12 and pro-autophagic lipid kinase VPS34 was not or only slightly increased 
in PHH after alcohol or FFA stimulation while alcohol and FFA together caused a 
marked increase (Figure 4.17). 
          (A)                                                  (B)                                                 (C) 
 
 
 
 
 
 
 
 
Figure 4.17 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, cells were co-incubated with 50 mM alcohol for additional 16 h. Analysis of 
heptocellular mRNA levels of (A) ATG7 (B) ATG12 and (C) VPS34 by quantitative RT-PCR.  (*: p< 
0.05 compared with control, #: p< 0.05 compared with FFA or alcohol). 
 
Very similar effects were observed in CYP2E1 expressing E47 cells, while neither 
alcohol or FFA alone nor their combination significantly affected ATG7, ATG12 or 
VPS34 expression in C34 cells without CYP2E1 (Figure 4.18). Also CMZ or NAC 
blunted the joint effect of alcohol and FFA on pro-autophagic gene expression 
(Figure 4.19). These findings suggest that joint effects of alcohol and FFA on 
CYP2E1 activation and subsequent ROS formation cause JNK-dependent 
induction of autophagy. 
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   (A)                                                    (B)                                                     (C)                                            
 
 
Figure 4.18 HepG2 E47 cells which express CYP2E1 or HepG2 C34 which don’t express CYP2E1 
were pre-incubated  with 0.2 mM oleate or BSA (served as control) for 24 h. Subsequently, cells 
were co-incubated with 50 mM alcohol for additional 16 h for mRNA analysis of (A) ATG7 (B) 
ATG12 and (C) VPS34 by quantitative RT-PCR.  
(*: p< 0.05 compared with corresponding control, #: p< 0.05 compared with FFA or alcohol in all 
experiment conditions). 
 
         (A)                                              (B)                                               (C)                  
 
 
Figure 4.19 HepG2 E47 cells which express CYP2E1 were pre-incubated with 0.2 mM oleate or 
BSA (served as control) for 24 h. Subsequently, some cells were co-incubated with 
Chlormethiazole (CMZ), a CYP2E1 inhibitor (100 µM) or N-acetyl cystein (NAC), a ROS scavenger 
(0.2mM) for 1 h before adding 50 mM alcohol to cultured medium for additional 16 h for mRNA 
analysis of (A) ATG7 (B) ATG12 and (C) VPS34 by quantitative RT-PCR. (*: p< 0.05 compared 
with corresponding control, #: p< 0.05 compared with FFA or alcohol in all experiment conditions). 
 
 
4.5.1 Inhibition of autophagy enhances the synergistic effects of alcohol 
and FFA on lipid accumulation, lipid peroxidation and hepatocellular 
inflammation  
To asses the functional role of autophagy in alcohol and FFA mediated effects on 
PHH; cells were pre-incubated with 2.5 mM 3-methyl adenine (3-MA), an 
autophagy inhibitor. 3-MA treatment enhanced basal as well as alcohol and FFA 
induced triglyceride accumulation, MDA and ICAM-1 levels in PHH (Figure 4.20).   
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               (A)                                                     (B)                                                  (C) 
 
Figure 4.20 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, some cells were co-incubated with 3-methyl adenine (3-MA), an autophagy inhibitor 
(2.5 mM) for 1 h before adding 50 mM alcohol to cultured medium for additional 24 h for (A) TG 
assay or (B) TBARS assay, or for additional 16 h for mRNA analysis of (C) ICAM-1 by quantitative 
RT-PCR. (*: p< 0.05 compared with corresponding control, $: p< 0.05 compared with the same 
condition in the inhibitor-untreated group. 
 
4.5.2 Induction of autophagy blunted the synergistic effects of alcohol and 
FFA on lipid accumulation, lipid peroxidation and hepatocellular 
inflammation  
Conversely, stimulation with the autophagy inducer rapamycin (2 µg/ml) slightly 
inhibited alcohol and FFA effects on these parameters (Figure 4.21).  Especially, 
joint effects of alcohol and FFA on triglyceride, MDA and ICAM-1 mRNA levels 
were completely blocked by rapamycin (Rapa) (Figure 4.21).   
          (A)                                                     (B)                                                  (C) 
 
Figure 4.21 PHH were pre-incubated with 0.2 mM oleate or BSA (served as control) for 24 h. 
Subsequently, some cells were co-incubated with rapamycin, an autophagy inducer (0.2 µg/ml) for 
1 h before adding 50 mM alcohol to cultured medium for additional 24 h for (A) TG assay or (B) 
TBARS assay, or for additional 16 h for mRNA analysis of (C) ICAM-1 by quantitative RT-PCR. (*: 
p< 0.05 compared with corresponding control, #: p< 0.05 compared with FFA or alcohol in all 
experiment conditions). 
 
These data together indicate that autophagy inhibits alcohol and FFA mediated 
effects on hepatocellular lipid-accumulation, lipid-combustion and pro-
inflammatory gene expression. 
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5 Discussion 
In this study, we developed a new in vitro model to study the effects of moderate, 
non-toxic alcohol levels on lipid-loaded and control hepatocytes and unraveled 
interacting effects between hepatocellular lipid accumulation and alcohol 
metabolism.  
Free fatty acids (FFAs) appear to be the major mediators of excessive hepatic lipid 
accumulation. The rate of hepatic FFA uptake is not regulated, and therefore, is 
proportional to plasma FFA concentrations (Teli et al., 1995). In humans with 
NAFLD, circulating FFAs are commonly elevated, and their plasma levels correlate 
with disease severity (Nehra et al., 2001). Already previously we had established 
an in vitro model of cellular lipid accumulation in primary human hepatocytes 
(PHH) and the human hepatoma cell line HepG2 by stimulation with free fatty 
acids (FFA) (Wobser et al., 2009). Here, we combined this model with alcohol 
stimulation. Also alcohol is known to induce hepatocellular lipid accumulation in 
vitro and in vivo (Lu et al., 2008; Wu et al., 2010; You et al., 2002) . Alcohol 
oxidation leads to acetyl-CoA synthesis from acetate or citrate that constitutes the 
substrates for lipogenic enzymes, and accordingly, we observed an increased 
expression of FASN and SCD-1 in alcohol stimulated PHHs. Also stimulation with 
FFA caused an increased expression of both enzymes but in combination with 
alcohol the induction was significantly stronger. Similarly, the induction of 
DGAT1/2 mRNA expression and cellular triglyceride levels was moderate upon 
stimulation with alcohol or FFA compared to the combination of both stimuli. 
Similar joint effects were observed on the expression of key enzymes of lipid 
peroxidation, which is known to cause ROS formation. Accordingly, also gene 
expression indicative for oxidative stress and cellular malondialdehyde (MDA) 
level was markedly increased by alcohol in combination with FFA stimulation while 
either of the two stimuli alone exhibited no or only slight effects. Moreover, we 
found alcohol and FFA jointly induced significantly more pro-inflammatory activity 
in hepatocytes than either of the two stimuli alone. Notably, joint effects of alcohol 
and FFA on cellular lipid accumulation and proinflammatory gene expression were 
dependent on CYP2E1 activity. CYP2E1 activity has been shown to correlate with 
alcohol-induced liver injury, and inhibition of CYP2E1 prevented induction of 
hepatic steatosis and ROS production in models of alcoholic steatohepatitis (Lu et 
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al., 2010; Lu et al., 2008; Wu et al., 2010). Also in NASH increased CYP2E1 
activity has been described and has been identified as a pathogenic factor (Aubert 
et al., 2011; Chalasani et al., 2003; Weltman et al., 1998). Interestingly, in our in 
vitro model CYP2E1 inhibition had only slight effects on hepatocellular lipid 
accumulation and MDA formation induced by only alcohol or FFA stimulation, 
respectively. In contrast, joint effects of alcohol and FFA on hepatic steatosis and 
lipid peroxidation were completely blunted. These effects indicate a crucial role of 
CYP2E1 and subsequent ROS production in the underlying pathophysiological 
mechanism of synergistic effects of alcohol and FFA. 
Noteworthy, we also observed an induction of autophagy in our in vitro system. 
Autophagy is a highly conserved intracellular catabolic pathway for the 
degradation of long-lived proteins and cytoplasmic organelles. It was found to 
promote lipid droplet degradation in hepatocytes (Dong and Czaja, 2011) and 
recent studies identified alcohol induced autophagy in primary hepatocytes as 
protective mechanism against ethanol-induced toxicity. Furthermore, this effect 
seemes to be selective for damaged mitochondria and accumulated lipid droplets, 
but not long-lived proteins, which could account for its protective effects (Ding et 
al., 2010). Moreover, induction of autophagy has been shown to reduce steatosis 
and to protect from hepatotoxicity in models of acute or chronic ethanol exposure 
(Ding et al., 2010; Wu et al., 2010; Yang et al., 2012). 
Similarly, inhibition of autophagy induced lipid accumulation, oxidative stress and 
inflammation, while induction of autophagy blunted these mechanisms in our in 
vitro model in hepatocytes. Under the experimental conditions used, which 
mimicked only moderate alcohol exposure and FFA induced steatosis, neither 
alcohol nor FFA alone caused induction of authophagy markers in hepatocytes, 
while the combination led to a marked up-regulation. Of note, this induction of 
autophagy required CYP2E1-mediated alcohol metabolism and ROS production 
that accordance with another study (Ding et al., 2010). Recently, another new 
strategy for treatment of alcohol-induced liver injury has emerged, namely the 
pharmacological inhibition of CYP2E 1 which has detrimental effects on the liver 
through free radical formation and lipid peroxidation (Gebhardt et al., 1997; 
Gouillon et al., 2000; Swaminathan et al., 2013). A recent study has shown also 
that pharmacological promotion of autophagy alleviated hepatic steatosis and 
injury in models of alcoholic as well as non-alcoholic fatty liver injuries (Lin et al., 
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2013). Our data suggest that induction of autophagy is an even more promising 
therapeutic concept in the presence of both chronic alcohol consumption and 
obesity. Still, the optimal treatment of alcohol induced liver injuries would be 
effective if we found a medication which is able to inhibit CYP2E1 activity and its 
subsequent ROS production on the one hand and to serve as an autophagy 
inducer on the other hand. 
 
In summary, in our model, alcohol and FFA act synergistically on hepatic lipid 
accumulation, lipid peroxidation, oxidative stress and inflammation. Conversely, 
alcohol and FFA jointly induce autophagy which inhibited these pathological 
mechanisms. Noteworthy, both detrimental as well as beneficial joint effect of 
alcohol and FFA are dependent on CYP2E1 activity. Therefore, manipulation of 
CYP2E1 activity in individuals with high BMI and/or metabolic syndrome and 
moderate alcohol consumption appears as a double edged sword. 
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7 Abbreviations 
Alc alcohol 
ACOX-1 acyl-Coenzyme A oxidase 1 
ADH alcohol dehydrogenase 
ALD alcoholic liver diseases 
ALDH aldehyde dehydrogenase 
ASH alcoholic steatohepatitis 
AST aspartate aminotransferase 
ALT alanine aminotransferase 
ATG autophagy-related genes 
BCA bicinchonic acid 
BMI Body Mass Induction 
°C         degree Celsius 
cDNA       complementary DNA 
CMZ Chloromethiazole 
CPT-1 carnitine palmitoyltransferase 1 
Ctrl   control 
CYP2E1 Cytochrome P450 2E1 
DGAT Diglyceride acyltransferase 
DMEM dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
EDTA ethylene diamine tetraacetic acid 
e.g exempli gratia 
ERK extracellular-signal-regulated kinases 
et al. et alii 
FASN Fatty acid synthase 
FCS fetal calf serum 
FFA free fatty acid 
g  gram 
G gravitational acceleration 
Abbreviations  62 
GOT glutamic oxaloacetic transaminase 
GPT glutamic pyruvic transaminase 
h hour 
HCC hepatocellular carcinoma 
HDL high density lipoprotein 
HMOX1  heme oxygenase (decycling) 1 
HSC hepatic stellate cells 
HRP horse radish peroxidise 
ICAM-1 inter-cellular adhesion molecule-1 
IL-8 interleukin-8 
IκBα inhibitory kappa B alpha 
IR insulin resistence 
IU unit international unit 
JNK c-Jun N-terminal kinases 
l liter 
LC3 light chain protein 3 
LPS lipopolysaccharide 
M molar; mol/l 
mA  miliampere 
MAPK mitogen-activated protein kinases 
MDA malondealdehyde 
mg milligram 
min minute 
mM milimolar 
mRNA messenger ribonucleic acid 
MS metabolic syndrome 
nm nanometer 
µg microgram 
µl microliter 
µM micro mollar 
NAC N-acetyl cystein 
NAD+ nicotinamide adenine dinucleotide (oxidized form) 
NADH nicotinamide adenine dinucleotide (reduced form) 
NAFLD non-alcoholic fatty liver disease 
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NaOH sodium hydroxide 
NASH non-alcoholic steatohepatitis 
NFκB nuclear factor kappa B 
OR Oil red O staining 
PAS phagophore assembly site 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI3K phosphatidylinositol 3-kinase 
PPAR peroxisome proliferator-activated receptor 
p47phox NADPH Oxidase Subunit p47phox 
q-RT-PCR quantitative real time PCR 
Rapa Rapamycin 
RNA ribonucleic acid 
ROS reactive oxygen species  
RT-PCR reverse transcription PCR 
SCD-1 Stearoyl-CoA desaturase 
TBARS Thiobarbituric acid reactive substances 
TNF tumor necrosis factor 
TG triglycerides 
V volt 
v/v volume/volume 
3-MA 3-methyl adenin 
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8 Appendix 
8.1 Curriculum Vitae 
 
Personal data: 
Name:                        Mahli  
First name:                 Abdo 
Nationality:                 Syrian 
Date of birth:              30.07.1983 
Place of birth:             Aleppo, Syria 
 
Education 
 
• Since Sep.2009: PhD Student in the Department of Internal Medicine I at 
the University Hospital of Regensburg, Germany. 
• Oct.2008 - Aug.2009: additional courses and exams in the Winter 
Semester 2008-2009 and the Summer Semester 2009 according to the 
decision of the doctoral committee of the Pharmacy Faculty in Regensburg, 
to obtain an approval for PhD position in Germany. 
• Jul.2007:  Diploma in Pharmacy and Pharmaceutical Chemistry  
      (Rate: very good) 
• Sep.2002 - Jul.2007: Study of Pharmacy and Pharmaceutical Chemistry, 
University of Aleppo, Major: Pharmaceutical industry, Minors: botany and 
biochemistry. 
• Jun.2002: Matriculation / Note 96.25%. 
• 1996 - 2002: Secondary school, Ebn Sina in Aleppo, Syria. 
• 1989 -1995: Elementary School, Abo Baker Al-Razi in Aleppo, Syria. 
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8.2 Presentation 
8.2.1 Oral Presentation 
• Cytochrome Cyp2e1 is critical for joint effects of alcohol and lipids on 
hepatocellular steatosis and inflammation 
Abdo Mahli, Michael Saugspier, Wolfgang E. Thasler, Martina Müller and Claus 
Hellerbrand  
Presented at the 68 th. Annual Meeting of the German Society for Digestive and Metabolic 
Diseases with Section endoscopy, Nürnberg, Germany (11 – 14.Sep, 2013) 
 
8.2.2 Poster presentation 
•  In vitro and in vivo models for irinotecan induced steatohepatitis  
Abdo Mahli, Michael Saugspier, Wolfgang Erwin Thasler, Martina Müller and Claus 
Hellerbrand 
Presented at the German Association of the Study of the Liver, Hannover, Germany (25-26.Jan, 
2013) 
 
• A novel in vitro model for joint effects of alcohol and free fatty acids on 
hepatocellular steatosis and inflammation 
Abdo Mahli, Wolfgang Erwin Thasler, Martina Müller, and Claus Hellerbrand  
Presented at the German Association of the Study of the Liver, Hannover, Germany (25-26.Jan, 
2013) 
 
• In vitro and in vivo models for chemotherapy-associated steatohepatitis 
expression reveal an effect of irinotecan on fatty acid binding protein 1  
Abdo Mahli, Michael Saugspier, Wolfgang E. Thasler and Claus Hellerbrand 
Presented at the International Liver Congress EASL, Barcelona, Spain (18-22.Apr, 2012) 
 
• Novel in vitro models of alcohol-mediated hepatic injury 
Abdo Mahli, Wolfgang Erwin. Thomas S. Weiss, and Erwin Gäbele Claus  Hellerbrand 
Presented at the German Association of the Study of the Liver, Hamburg, Germany (27-28.Jan, 
2012) 
 
• Hepatocellular lipid accumulation enhances the susceptibility for 
oxaliplatin-induced hepatic injury 
Abdo Mahli, Christoph Dorn and Claus Hellerbrand 
Presented at Falk workshop for Inflammation and Cancer, Hamburg, Germany (26-27.Jan, 2012) 
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• A novel in vitro model of alcohol-induced hepatic fibrogenesis 
Abdo Mahli, Karin Dostert, Thomas Weiss, Wolfgang Thasler, Erwin Gäbele,   and Claus 
Hellerbrand 
Presented at the German Association of the Study of the Liver, Regensburg, Germany (28-29.Jan, 
2011) 
 
• The hop chalcone xanthohumol beneficially affects hepatocellular lipid 
metabolism 
Abdo Mahli, Christoph Dorn, Michael Saugspier, Thomas Weiss, Wolfgang Thasler, Jörg 
Heilmann, and Claus Hellerbrand 
Presented at the German Association of the Study of the Liver, Regensburg, Germany (28-29.Jan, 
2011) 
 
8.3 Courses 
• Advanced training course for being project manager and awareness of 
biological safety conditions, Regensburg, Germany, (15 -16.Apr, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix  67 
Eidesstattliche Erklärung 
Familienname: Mahli  
Vorname: Abdo  
Geburtsdatum: 30.07.1983 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Arbeit ohne unzulässige 
Hilfe Dritter und ohne Benutzung anderer als der angegebenen Hilfsmittel 
angefertigt habe; die aus anderen Quellen direkt oder indirekt übernommenen 
Daten und Konzepte sind unter Angabe des Literaturzitats gekennzeichnet (Siehe 
Kapitel „References“).  
Bei der Auswahl und Auswertung folgenden Materials haben mir die nachstehend 
aufgeführten Personen in der jeweils beschriebenen Weise 
entgeltlich/unentgeltlich geholfen:  
1-.........  
2-.........  
3-.........  
Weitere Personen waren an der inhaltlich-materiellen Herstellung der vorliegenden 
Arbeit nicht beteiligt. Insbesondere habe ich hierfür nicht die entgeltliche Hilfe 
eines Promotionsberaters oder anderer Personen in Anspruch genommen. 
Niemand hat von mir weder unmittelbar noch mittelbar geldwerte Leistungen für 
Arbeiten erhalten, die im Zusammenhang mit dem Inhalt der vorliegenden 
Dissertation stehen.  
Die Arbeit wurde bisher weder im In- noch im Ausland in gleicher oder ähnlicher 
Form einer anderen Prüfungsbehörde vorgelegt.  
Ich versichere an Eides statt, daß ich nach bestem Wissen die reine Wahrheit 
gesagt und nichts verschwiegen habe.  
Vor Aufnahme der obigen Versicherung an Eides statt wurde ich über die 
Bedeutung der eidesstattlichen Versicherung und die strafrechtlichen Folgen einer 
unrichtigen oder unvollständigen eidesstattlichen Versicherung belehrt.  
 
Regensburg, den 21.11.2014 
 
